Chagas' disease results from the infection of the protozoan parasite Tr,/panosoraa cruzi and affects several million people in South America. Several alterations of the immune response have been described in this disease, such as severe immunosuppression of both cellular and humoral responses and massive polyclonal stimulation with the generation of autoantibodies crossreacting with host cells and tissues. We have obtained monodonal antibodies (mAbs) from T. cruzi-infected mice that recognized a 50/55-kD antigen (GP50/55) on the T. cruzi membrane, but not in other parasites of the family Trypanosomatidae. One of these GPS0/55-specific mAbs (C10) crossreacts with a 28-kD antigen (p28) expressed on the membrane of >85% of activated mouse T and B lymphocytes, after in vitro activation with concanavalin A, Salmonella typhosa lipopolysaccharide, phorbol dibutyrate ester, or antigen, and on several murine T and B lymphocyte cell lines. Human T and B lymphocytes also express upon activation with phytohemagglutinin or Staphylococcus aureus Cowan I (SAC) a similar antigen recognized by mAb C10, although in a lower proportion of ceils (30-40%). Furthermore, this mAb was able to suppress mouse and human T and B cell proliferation to any of those stimuli. In addition, sera from chagasic patients and T. cruz/-infected mice, but not from control patients or littermates, contain antibodies that recognize a similar p28 antigen on B lymphocytes. Furthermore, the immunoglobulin fractions of some chagasic sera also suppress the proliferation of human T lymphocytes. These results suggest a possible pathological role of autoantibodies as an alternative mechanism for T. cruzi-associated immunosuppression.
T rypanosoraa cruzi is the causal agent of the Chagas' disease, which affects several million people in Central and South America (1) . This protozoan parasite has a complex life cycle and exists in at least three morphologically distinct forms: infective (metacyclic or blood trypomastigotes), insect borne (epimastigotes), and intracdlular replicative (amastigotes), which grows and replicates inside a variety of mammalian cells (1) .
From a clinical point of view, the T cruzi infections proceed in two phases. In the acute phase, circulating blood trypomastigotes are observed and there is a local inflammation at the sites of infection (1) . During the chronic phase, circulating parasites cannot be observed by inspection of blood but progressive tissue damage occurs involving the esophagus, colon, and heart (1) .
An autoimmune mechanism in the pathogenesis of human and experimental models of chronic Chagas' disease has been proposed (2, 3) , but the exact role that this mechanism plays in disease production is not clear. A massive polyclonal activation ofT and B lymphocytes (4) with an increased production of autoantibodies (5) , together with a severe immunosuppression of the humoral and cellular responses (6) have been described in the acute phase of Chagas' disease, although the importance of those phenomena on the pathology of the disease is still poorly understood (6, 7) .
On the other hand, there are many examples of antibodies from sera of T. cruzi-infected patients or animals that have been shown to react with host nervous and cardiac tissue antigens (8) (9) (10) (11) (12) (13) (14) (15) . In addition, T cells that are crossreactive with cardiac or nerve cells have been also found in mice with experimental Chagas' disease (16, 17) , which can transfer the tissue pathology to naive animals (16) . This has led to the hypothesis that T, cruzi has crossreactive antigens that mimic host molecules, which are responsible for the tissue damage associated with the chronic phase of Chagas' disease (2, 3) , when virtual absence of parasites exists. The origin of the autoimmunity in Chagas' disease is not yet understood but it is likely that the polyclonal stimulation caused by the para-site in the acute phase of T. cruzi infection (4) is responsible for the origin of this apparent breakdown of stir-tolerance (18) . Thus, it has been proposed that the combined effects of the polydonal stimulation and the chronic presence of crossreactive antigens give rise to the autoimmune pathology of Chagas' disease (18) . Therefore, it is important to characteri~ these crossreactive antigens in order to get a clearer understanding of their function in the etiology of this disease in the chronic phase.
In a previous work (19), we described four mAbs that recognize a 50/55-kD antigen (GP50/55) on T. cruzi membrane. We describe in this manuscript that one of these GP50/55-specific mAbs crossreacts with an activation antigen present on T and B lymphocyte membranes and is able to suppress polyclonal T and B proliferation. Furthermore, antibodies with similar specificity are present in the sera from chagasic patients and from infected mice. This is the first description of a T, cruzi-specific mAb that recognizes an activation antigen of T and B lymphocytes, and our results suggest a possible pathological role of autoantibodies as an alternative mechanism for T cruzi-assodated immunosuppression. gium). The irrelevant mouse IgG1 (P3) was obtained from the hybridoma P3X63AgS. The rabbit F(ab')2 anti-mouse Ig-FITC and the goat anti-rat Ig-FITC antibodies were purchased from Southern Biotechnology (Birmingham, AL).
The mAbs C10 and I>3 were purified by affinity chromatography with protein A-Sepharose CL4B (Sigma Chemical Co., St. Louis, MO), and they were biotinylated with N-hydroxysuccinimido biotin (Sigma Chemical Co.).
Human chagasic sera were obtained from Argentina and Colombia and were a gift from Drs. C. Alonso, J. M. Requena (Centro de Biologia Molecular, Madrid, Spain), and M. L6pez (Instituto Lrpez-Neyra, Granada, Spain). The Ig fraction was purified by affinity chromatography with anti-human Ig (Nordic, Tilburg, UK) covalently coupled to protein A-Sepharose CL4B by using dimethyl-dipimelimidate as crosslinker agent.
Cytofluorimetry Analysis. Cells (1-2 x 10 s) or parasites (1-2 x 10 +) were centrifuged three times in PBS with 2% BSA and 0.1% sodium azide. They were subsequently incubated with 50/~g/ml of biotin-labeled mAb C10, or biotin-labeled control mAb P3, or nonlabeled antibodies diluted in the same buffer, for 30 rain at 4~ Cells or parasites were washed in the above buffer and incubated again with 50/~1 of streptavidin-PE or 50/zl rabbit anti-mouse F(ab')z Ig-FITC or goat anti-rat Ig-FITC (Southern Biotechnology) diluted in the same buffer, for 30 rain at 4~ in the dark. After three rinses, the parasites or ceils were resuspended in the same buffer containing 1% paraformaldehyde, and the fluorescence was analyzed in an EPICS cytofluorimeter (Coulter Scientific, Harpeden, UK). Detailed combination of reagents for the doubh-color staining is described in the legend of Fig. 3 .
Immunoprecipitations. Parasites (2 x 10 s epimastigotes) or cells (2 x 107) were labeled with 12sI by the lactoperoxidase method (19) . The immunoprecipitations of T. cruzi antigens were carried out using preformed protein A-Sepharose Cb4B (Sigma Chemical Co.) antibodies complexes as described (19) . For immunoprecipitation from labeled murine cells, these were divided in two aliquots of 2 ml in PBS, and 50-100/zg of purified mAb C10 or irrelevant mouse IgG1 mAb were added. The samples were incubated for 2 h at 4~ Cells were washed three times with PBS and were disrupted in 1 ml of lysis buffer containing 1% NP-40 (19) . The immunoprecipitation of cell antigen was carried out as described (19) .
Proliferation Assays. BALB/c mice were immunized intraperitoneally with a T. cruzi extract obtained from 107 epimastigotes per mouse in PBS mixed with CFA at day 0. At day 28, mice were immunized in the same way but substituting CFA for IFA. At the day 42, mice were finally injected intraperitoneally with the T. cruzi extract without adjuvants. Mice were killed by COs inhalation 15 d after the last immunization. Spleens were removed, the RBC were eliminated by hypotonic shock, and the spleen cells were activated in vitro with Con A, phorbol dibutyrate ester (PDBu), ~ LPS, or parasite lysates at the indicated concentrations in the presence of different concentrations of antibodies.
Human PBL were obtained from heparinized venous blood of healthy volunteers by Ficoll-Hypaque centrifugation as described (24) . Human T cells were activated with different concentrations of PHA (Sigma Chemical Co.) in the presence of the indicated concentrations of the antibodies. Human B cells were obtained from human tonsils of children 4-10 yr old, and the cells were activated with Staphylococcus aureus Cowan I (SAC) (Calbiochem-Behring Corp., San Diego, CA) as described (25) .
The proliferation assays were carried out in 96-well U-shaped microtiter plates (Flow Laboratories, Inc.) containing 100 #l/weU with 1-5 x 10 s cells in complete RPMI 1640 with 10% FCS and 5 x 10 -s M 2-ME. The cultures were maintained at 37~ in a humidified atmosphere containing 5% CO2 for 24-96 h. Cell proliferation was estimated by the amount of [3H]thymidine (New England Nuclear, Boston, MA) incorporated during the last 4-16 h of culture. Cells were harvested, and the radioactivity incorporated into DNA was measured in a liquid scintillation counter.
Results
The 77. cruzi-specific mAb CIO Is Crossreactive with an Activation Antigen Present on T and B Lymphocytes. We have obtained mAbs from T cruzi-infected mice with the aim of searching for those that were crossreactive with host cells. For this purpose, BALB/c mice were infected with the T. cruzi G strain and hybridomas were first selected by thdr ability to secrete antibodies that bind specifically to intact parasites (19) . To search for autoreactivity, the binding of these mAbs against a pand of transformed mouse call lines from distinct tissue origins was tested by cytofluorimetry analysis. One of these mAbs, termed mAb C10, strongly reacted with 99% of the intact T. cruzi epimastigotes (Fig. 1) . mAb C10 reacted with all the morphological forms of the parasite: trypomastigotes, amastigotes, and epimastigotes (19) . This mAb was T. cruzi specific since it did not react with other closely related protozoa belonging to the Trypanosomatidae family, such as L. mexicana ( Binding of mAb C10 to cell lines was assayed by flow cytometry. Calls (1-2 x 10 s) were washed as described in Materials and Methods. Then, they were stained with biotin-labeled mAb C10 or biotin-hbded control mouse IgG1, for 30 rain at 4~ Cells were incubated with streptavidin-PE diluted 1/300 for 30 rain at 4~ in the dark. The fluorescence was analyzed in an EPICS cytofluorimeter. The percent of positive cells shown was calculated by subtracting the binding of the irrelevant control.
origin were negative (Table 1 ). This result prompted us to test the reactivity of the mAb C10 with normal T and B lymphocytes from BALB/c mouse spleen. As shown in the Fig. 2 , a very small percent (6-13%) of cells in a normal spleen were positive for this antibody. By contrast, this percentage rose to 85% or more after 96 h of in vitro activation with PDBu, with the T cell mitogen Con A, or with the B cell mitogen Salmonella typhosa LPS (Fig. 2) . The binding of mAb C10 to the membrane of activated mouse lymphocytes was not due to the recognition of the Con A or LPS used in the stimulation, because the crossreactive mAb C10 antigen was also induced by phorbol ester stimulation, and Con A or LPS were unable to affect the mAb C10 binding to either DO-10.11 or Sp2/0 + cells (data not shown). negative. Therefore, the lymphocyte antigen recognized by mAb C10 is present in both activated mouse B and T cells.
By double-color cytofluorimetry analysis, the mAb C10 antigen was first dearly detected on the membrane of Ig + B mouse cells after 48 h of LPS activation. This expression rose strongly after 72 h and it was maximal 96-120 h after the addition of the stimulus (Fig. 3) . These results also indicated that all Ig + cells expressed mAb C10 antigen. Similar results in the kinetic of mAb C10 expression were obtained after PDBu or Con A stimulation (data not shown).
Despite the lack of reactivity of human T and B cell lines with mAb C10, we tested the effect on normal human PBL stimulated with T and B cell mitogens. As seen in Fig. 4 , resting human lymphocytes were weakly stained with the antibody. However, after 48 h of in vitro activation with PHA or SAC, 30-40% of both T and B cells were positive, and this percent, in contrast to the mouse system, did not increase with longer stimulation times. These activated cells were strongly positive for other activation antigen markers, such as 4F2 or CD25, 65-85%, (data not shown), therefore discarding inefficient activation as the cause of the lower percent observed with human lymphocytes. Interestingly, mAb C10 antigen expression on the membrane of activated human T cells was stronger than activated human B cells. mAb C10 recognized a GP50/55 T. cruzi glycoprotein that is linked to the membrane by a glycosyl-phosphatidylinositol anchor (19) . This antigen can be immunoprecipitated by mAb C10 from tzsI-labeled T. cruzi lysates (Fig. 5) . By contrast, a faint but detectable band *28 kD was specifically immunoprecipitated by mAb C10 from intact Sp2/0 + (Fig. 5) or DO-11.10 (data not shown) |25I-labeled cells. Similar results were obtained under reducing or nonreducing conditions (data not shown). mAb C101s Able to lnhibit T and B CelI Proliferation. Since the antigen detected by mAb C10 was present in almost 90% of activated mouse spleen cells, we tested the functional effects of mAb C10 on T and B cell activation. Concentrations of purified antibody as low as 0.5 #g/ml were able to induce maximum inhibition of the mouse spleen cell proliferation to Con A as measured by incorporation of [3H]thymidine into DNA 72 h later (Fig. 6 ). Spleen cells from BALB/c mice previously immunized with T. cruzi, as described in Materials and Methods, were activated in vitro with either Con A, LPS, PDBu, T cruzi, or L. mexicana extracts. As seen in Fig.  7 , these immune spleen cells proliferated in response to Con A, LPS, PDBu, or the appropriate antigen (T. cruzi extracts), but not to L. mexicana extracts. When purified mAb C10 [oglo fluorescence intensity
Figm'e 4. mAb C10 antigen expression on activated human T and B lymphocyt~ Human T and B cells were obtained as described in Materials and Methods and we~ activated in vitro by incubating with PHA (2/~/ml) or Staf~/oc~cus morus Cowan I (1 ttg/ml) in complete RPMI 1640 containing 10% FCS. The cultures were maintained at 37~ in a humidified atmosphere containing 5% CO2, for 48 h. The cells w e e e stained and analyzed as described in Fig. 1 . The staining pattern of resting PBL or tonsil lymphocytes is shown in a and b, respectively; c and d show the staining of PHA-activated PBL and SACI-activated tonsil lymphocytes. The white and black profiles represent the fluorescence staining obtained with the control P3 mAb or mAb C10, respectively. The percent ofmAb C10-pofirive cells and the mean fluorescence intensity for each cell popuhtion are shown inside the corresponding panel.
(1/~g/ml) was added to the cultures, a similar inhibition of the proliferation to all stimuli was observed. The kinetic of this proliferative inhibition by the mAb C10 correlated with the kinetic of appearance on the cell membrane of the mAb C10 crossreactive antigen in those immune spleen cells (Fig. 8) . The inhibition of T cell proliferation to Con A by mAb C10 was not observed during the first 24 h of culture. It was first detected after 48 h and was maximal after 72 or 96 h (Fig. 8) . Similar results were obtained with the stimulation of B calls with LPS (data not shown).
Antibodies with Similar Specificity to mAb C10 Exist in Human Ckagasic Sera and in T. cruzi-infected Mice Sera.
To test the presence of antibodies with similar antigenic specificity to mAb C10 in the sera of chagasic patients and infected mice, inhibition experiments of the binding of biotinylated mAb C10 to intact parasites and cells were carried out. As seen in Fig. 9 and Table 2 , sen of T. cruz/-infected mice and humans were able to block specifically mAb C10 binding both to lymphocytes and to T. cruz/epimastigotes, detected by cytofluorimetry analysis. Furthermore, the binding of other antibodies to different surface molecules such as mAb M1/9.3.4.HL.2 (anti-murine CD45) ( Fig. 9 and Table 2 ), anti-H-2 a or antiIad (data not shown) on lymphocyte membranes was unaffected. All sera from the chagasic patients tested (5/5) were able to, specifically and significantly, block the binding of mAb C10 to T. cruzi and Sp2/0 § independently of their titer of antibodies against T. crv, zi. Sera from human controls of the same area were negative (2/2). Furthermore, sera from T. cruzi-immune mice were less effective than sera from infected mice in blocking mAb C10 binding, despite the fact that immune sera had 300 times higher anti-T, cruzi antibody titer (Table 2 ). To further confirm the specificity of the antibodies present in the chagasic sera, we purified the Ig fraction of the sera, and that fraction was tested in the proliferation of human PBL. mAb C10 was able to inhibit (40-50%) PHA-dependent prolifemion of human T cells, in a percent similar to the percent ofmAb C10-positive lymphocytes (40%) among these activated cells (Fig. 10) . Similarly, purified Igs from the sera of two chagasic patients, but Igs not from normal sera, also inhibited, in a dose-response manner, PHA proliferation (Fig.  10) . Of purified Igs from 14 chagasic sera tested, 50% of them had similar inhibition to the two shown in Fig. 10 , whereas four were without effect and three were weakly inhibitory (data not shown).
Discussion
It is likely that the combined effects of the polyclonal stimulation and the chronic presence of crossreactive antigens could account for the autoimmune pathology of Chagas' disease (18) . To get a clearer understanding of the function of selfreactive antibodies in the etiology of this disease, we have obtained mAbs from T. cmzi-infected mice with the aim of characterizing the relevant parasite antigens.
Although several T. cruzi-specific antibodies that crossreact Our data also re&care that ant,bo&es w~th slm,lar reactw~ty to mAb C10 may ernst m the sera of infected m&vxd-uals and animals Ths hypothem ~s supported by the fact that (a) antlbo&es m chagas~c sera but not m control sera were able to block specifically mAb C10 binding, both to lymphocytes and to T. cruz~ ep~masugotes (Table 2 ) It ~s very unhkely that the competmon for the binding of mAb C10 to two &fferent molecules, GP50/55 m T. cruz= and p28 on lymphocytes, by chagastc sera was due to stenc reasons since the binding of other surface molecules, such MHC anugens or CD45, htghly abundant on the lymphocyte surface, were unaffected Therefore, ~t is hkely that the Igs of the chagaslc sera contain anubodtes of slmdar speoficaty to mAb C10, although it ~s very dff~cult to completely ascertain d the anubo&es m chagas~c sera recogmze or not the same epltope that the mAb C10 recogmzes (b) Ant~bo&es m some chagas~c sera but not m control sera were able to suppress human T cell prohferatwe responses as mAb C10 &d Obv~ousl3r, ths mhbmon could be due to many other Igs with different spec~ficaues in those sera, since ~t ~s very difficult to prove beyond a reasonable doubt that the anubodxes are bmdmg to the same epltope that mAb C10 does The reason that only 50% of the sera were inhibitory could be related to the &fferent tlters of Igs with mAb C10-hke reacuwty m the &fferent sera. In general, the sera that rabbited T cell prohferauon were the ones that had stronger mhlbiuons of mAb C10 binding to lymphocytes Alternatively, since it is known that there are at least two chmcal mamfestauons of the &s-ease, ~t ~s possible that ths is potenually related to our results Furthermore, although this inhibition was low, it correlated w~th the percent of mAb C10-posmve cells m those acuvated popuhuons, which also supported the nouon that the Igs of those sera were blocking prohferauon through mAb C10 binding. Taking all together, our data support the nouon that anubo&es against p28 oust m cbagas~c pauents and mice and could contribute at least m part to the observed ~mmunosuppress~on It ~s worth noting that the sera from T cruzi-tmmune mlce were less effecuve than serum from infected mice m blocking mAb C10 binding, despite the fact that tmmune serum had 300 umes higher anu-T cruz= anubody uter. This is m agreeq. Ioglo fluorescence intensity ment with the fact that only a small percent (1/4) of mAbs against GP 50/55 (19) are crossreactive with p28 (Hern~ndez-Munafn et al., unpublished results). Besides, these results confirm the importance of studying antibody repertoire from infected animals instead of from immunized animals. It has been shown that a T. cruzi infection does not have the same effects in the immune system as an exposition to dead microorganisms (27) . Therefore, our results confirm that an active infection induces antibodies with a different repertoire of antigenic specificities to those of classical immunizations. Our data suggest that T. cmzi presents antigens on its membrane that can induce crossreactive antibodies to the surface antigens of T cruzi-activated lymphocytes during the infection and inhibit their proliferation. This phenomenon is of particular interest in as much as the specific recognition of lymphocyte membrane receptors by autoantibodies may result in modulation of immune response in Chagas' disease. It has been suggested that Chagas' disease may have an immunological basis (2, 3, 6, 7) . Severe immunosuppression of the immune responses in the acute phase of the infection Binding of mAbs C10 or M1/9.3.4.HL.2 (anti-murine CD45) to T. cruzi or SP2/0 § membrane was studied by flow cytometry analysis. 1-2 x 106 T. cruzi epimastigotes or 1-2 x 10 s Sp2/0 + cells were resuspended and incubated with 100 #1 of each sera diluted 1/10 in PBS with 2% BSA and 0.1% sodium azide for 1 h at 4~ After three washes with the same buffer, the parasites or cells were incubated with 10 #g/ml biotin-labded mAb C10 or mAb M1/9.3.4.HL2 for 30 rain at 4~ The parasites or cells were washed and incubated for 30 min at 4~ in the dark with streptavidin-PE or goat anti-rat IgFITC, respectively. The fluorescence was analyzed in an EPICS cytofluorimeter. The titer shown refers to the antibody titer against T. cruzi determined by ELISA as described (19) . has been reported (28) (29) (30) (31) (32) (33) (34) (35) (36) . This immunosuppression is thought to diminish the resistance of the host to the establishment and dissemination of the disease. However, the molecular basis for this immunosuppression is not well understood. These effects have been attributed to impaired Ib2 production due to the presence of suppressor cells: either macrophages (28) (29) (30) or T cells (31) (32) (33) (34) (35) , or to T. cruz/immunosuppressive factors (36) . Another mechanism could be the polyclonal activation of lymphocytes that may alter the reactivity against foreign antigens causing the immune system to respond poorly to further antigenic challenge due to a state of refractoriness (4) . The results shown in this manuscript add a new potential mechanism to explain this immmunosuppression. The presence in &agaric sera of T. cruzi-specific antibodies with similar properties as mAb C10 could theoreticaUy be able to suppress T and B cell activation like mAb C10 does in vitro and may account for the suppression of the immune response. Alternatively, they may indirectly contribute to the immunosuppression by eliminating activated lymphocytes through complement-mediated killing. Recently, a mAb against another pathogen with similar functional properties to mAb C10 has been described (37) . This antibody, specific for a measles virus protein, crossreacts with a T lymphocyte subset also causing immunosuppression. This crossreactivity has been also suggested to play a role in the etiology of measles-induced immunosuppression in vivo (37) .
The 28-kD antigen recognized by mAb C10 on T and B lymphocytes seems to represent a yet undescribed activation antigen at least in mice. This antigen appears late after activation with several mitogenic activators and seems to be involved in the regulation of the late stages of lymphocyte proliferation. Among those, mAb C10 blocks II~2-dependent proliferation of T cells (Hern~ndez-Munatn et al., manuscript in preparation). A somewhat similar activation antigen, CDw70, has been described in human T and B lymphocytes (38) ; this antigen, like mAb C10 antigen, is present in T-and B-activated lymphocytes but absent in thymocytes (38) (Fig. 2 and data not shown) . The described molecular mass of CDw70, detected by immunoblot techniques, is "~30 kD, similar to that of mAb C10 antigen. Furthermore, antiCDw70 antibodies have inhibitory activity on lymphocyte proliferation like mAb C10. Recently, a 26-kD TAPA-1 antigen has been described in human T and B cells (39) that also shares some similarities with mAb C10 lymphocyte antigen. Experiments are in progress to further characterize the p28 antigen.
In summary, our results show the existence of an antibody specific for T. cruzi that is crossreactive with an activation antigen present on T and B lymphocytes. This may have implications in the understanding of the complex pathology of this disease. Our data suggest that T. cruzi presents antigens on its membrane that can induce crossreactive antibodies to the surface antigens of T. cruzi-activated lymphocytes during the infection altering their functionality.
